STEMI Clinical Trial
Official title:
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction: A Single-center，Randomized,Open-label Trial
Acute ST-segment elevation myocardial infarction (STEMI) is a common manifestation of cardiovascular emergencies. Percutaneous coronary intervention (PCI) and guideline-recommended pharmacotherapy have reduced mortality rates associated with STEMI, but the incidence of recurrent ischemic events, particularly early ischemic events, remains high. Current research suggests that low-density lipoprotein cholesterol (LDL-C) levels not meeting guideline-recommended levels and inflammation are closely related to early recurrent ischemic events. Evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, rapidly and effectively reduces LDL-C levels and suppresses inflammation. Long-term use in patients with acute coronary syndromes can reverse atherosclerosis and improve prognosis. However, data on its use in STEMI patients are limited, particularly regarding the cardioprotective effects of preoperative administration of 420mg evolocumab subcutaneous injection. This study aims to evaluate the effects of administering evolocumab 420mg before emergency PCI on lipid profiles, inflammatory markers, myocardial injury, and short-term prognosis in STEMI patients through a single-center, randomized, open-label study. It aims to provide theoretical evidence for further reducing the risk of recurrent cardiovascular events in STEMI and identifying more optimized treatment strategies.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
| Completed |
NCT01452139 -
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
|
Phase 2/Phase 3 | |
| Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A | |
| Completed |
NCT01625104 -
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
|
N/A | |
| Completed |
NCT04023266 -
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
|
Phase 2 | |
| Completed |
NCT02170103 -
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
|
N/A | |
| Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
| Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
| Enrolling by invitation |
NCT03328156 -
Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction
|
N/A | |
| Completed |
NCT04017169 -
No Reflow Phenomenon Incidence and Predictors
|
||
| Completed |
NCT03470441 -
A Study of Acute Myocardial Infarction Using FDY-5301
|
Phase 2 | |
| Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
| Completed |
NCT01197742 -
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
|
N/A | |
| Terminated |
NCT03439150 -
Resistance STEMI Study
|
N/A | |
| Recruiting |
NCT03998319 -
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
|
Phase 3 | |
| Not yet recruiting |
NCT05974930 -
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
|
||
| Active, not recruiting |
NCT03102723 -
Platelet Inhibition to Target Reperfusion Injury
|
Phase 2 | |
| Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
| Not yet recruiting |
NCT04912167 -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
|
Phase 3 | |
| Completed |
NCT02942550 -
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
|
Phase 4 |